Methods for the early diagnosis of ovarian cancer

Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C435S007400, C435S023000, C435S006120, C530S350000

Reexamination Certificate

active

06294344

ABSTRACT:

BACKGROUND OF THE INVENTION
1. Field of the Invention
Generally, the present invention relates to the fields of molecular biology and medicine. More specifically, the present invention is in the field of cancer, especially ovarian cancer diagnosis.
2. Background of the Invention
To date, ovarian cancer remains the number one killer of women with gynecologic malignant hyperplasia. Approximately 75% of women diagnosed with such cancers are already at an advanced stage (III and IV) of the disease at their initial diagnosis. During the past 20 years, neither diagnosis nor five year survival rates have improved greatly for these patients. This is substantially due to the high percentage of high-stage initial detections of the disease. Therefore, the challenge remains to develop new markers that improve early diagnosis and thereby reduce the percentage of high-stage initial diagnoses.
Extracellular proteases have already been implicated in the growth, spread and metastatic progression of many cancers, due to the ability of malignant cells not only to grow in situ, but to dissociate from the primary tumor and to invade new surfaces. The ability to disengage from one tissue and re-engage the surface of another tissue is what provides for the morbidity and mortality associated with this disease. Therefore, extracellular proteases may be good candidates for markers of neoplastic development.
In order for malignant cells to grow, spread or metastasize, they must have the capacity to invade local host tissue, dissociate or shed from the primary tumor, and for metastasis to occur, enter and survive in the bloodstream, implant by invasion into the surface of the target organ and establish an environment conducive for new colony growth (including the induction of angiogenic and growth factors). During this progression, natural tissue barriers have to be degraded, including basement membranes and connective tissue. These barriers include collagen, laminin, proteoglycans and extracellular matrix glycoproteins, including fibronectin. Degradation of these natural barriers, both those surrounding the primary tumor and at the sites of metastatic invasion, is believed to be brought about by the action of a matrix of extracellular proteases.
Proteases have been classified into four families: serine proteases, metallo-proteases, aspartic proteases and cysteine proteases. Many proteases have been shown to be involved in the human disease process and these enzymes are targets for the development of inhibitors as new therapeutic agents. Additionally, certain individual proteases have been shown to be induced and overexpressed in a diverse group of cancers, and as such, are potential candidates for markers of early diagnosis and possible therapeutic intervention. A group of examples are shown in Table 1.
TABLE 1
Known proteases expressed in various cancers
Gastric
Brain
Breast
Ovarian
Serine Proteases:
uPA
uPA
NES-1
NES-1
PAI-1
PAI-1
uPA
uPA
tPA
PAI-2
Cysteine Proteases:
Cathepsin B
Cathepsin L
Cathepsin B
Cathepsin B
Cathepsin L
Cathepsin L
Cathepsin L
Metallo-proteases:
Matrilysin*
Matrilysin
Stromelysin-3
MMP-2
Collagenase*
Stromelysin
MMP-8
Stromelysin-1*
Gelatinase B
MMP-9
Gelatinase A
uPA, Urokinase-type plasminogen activator; tPA, Tissue-type plasminogen activator; PAI-I, Plasminogen activator 0 inhibitors; PAI-2, Plasminogen activator inhibitors; NES-1, Normal epithelial cell-specific-1; MMP, Matrix P metallo-protease. *Overexpressed in gastrointestinal ulcers.
Significantly, there is a good body of evidence supporting the downregulation or inhibition of individual proteases and the reduction in invasive capacity or malignancy. In work by Clark et al., inhibition of in vitro growth of human small cell lung cancer was demonstrated using a general serine protease inhibitor. More recently, Torres-Rosedo et al., [
Proc. Natl. Acad. Sci. USA
, 90, 7181-7185 (1993)] demonstrated an inhibition of hepatoma tumor cell growth using specific antisense inhibitors for the serine protease hepsin gene. Metastatic potential of melanoma cells has also been shown to be reduced in a mouse model using a synthetic inhibitor (batimastat) of metallo-proteases. Powell et al. [
Cancer Research
, 53, 417-422 (1993)] presented evidence to confirm that the expression of extracellular proteases in relatively non-invasive tumor cells enhances their malignant progression using a tumorgenic, but non-metastatic, prostate cell line. Specifically, enhanced metastasis was demonstrated after introducing and expressing the PUMP-1 metallo-protease gene. There is also a body of data to support the notion that expression of cell surface proteases on relatively non-metastatic cell types increases the invasive potential of such cells.
Thus, the prior art is deficient in a tumor marker useful as an indicator of early disease, particularly for ovarian cancers. The present invention fulfills this long-standing need and desire in the art.
SUMMARY OF THE INVENTION
This invention allows for the detection of cancer, especially ovarian cancer, by screening for stratum corneum chymotrytic enzyme (SCCE) mRNA in tissue, which is indicative of stratum corneum chymotrytic enzyme specifically associated with the surface of 80 percent of ovarian and other tumors. Proteases are considered to be an integral part of tumor growth and metastasis, and therefore, markers indicative of their presence or absence are useful for the diagnosis of cancer. Furthermore, the present invention is useful for treatment (i.e., by inhibiting SCCE or expression of SCCE), for targeted therapy, for vaccination, etc.
In one embodiment of the present invention, there is provided a method of diagnosing cancer in an individual, comprising the steps of obtaining a biological sample from the individual and detecting stratum corneum chymotrytic enzyme in the sample. Usually, the presence of stratum corneum chymotrytic enzyme in the sample is indicative of the presence of carcinoma in the individual, and the absence of stratum corneum chymotrytic enzyme in the sample is indicative of the absence of carcinoma in the individual.
In another embodiment of the present invention, there is provided a method for detecting malignant hyperplasia in a biological sample, comprising the steps of isolating mRNA from the sample and detecting stratum corneum chymotrytic enzyme mRNA in the sample. Typically, the presence of the stratum corneum chymotrytic enzyme mRNA in the sample is indicative of the presence of malignant hyperplasia, and the absence of the SCCE mRNA in the sample is indicative of the absence of malignant hyperplasia.
In yet another embodiment of the present invention, there is provided a method for detecting malignant hyperplasia in a biological sample, comprising the steps of isolating protein from the sample and detecting stratum corneum chymotrytic enzyme protein in the sample. Generally, the presence of the SCCE protein in the sample is indicative of the presence of malignant hyperplasia, wherein the absence of the SCCE protein in the sample is indicative of the absence of malignant hyperplasia. This method may further comprise the step of comparing the SCCE protein to reference information, wherein the comparison provides a diagnosis of the malignant hyperplasia, or alternatively, determines a treatment of the malignant hyperplasia.
In still yet another embodiment of the present invention, there is provided a method of inhibiting expression of stratum corneum chymotrytic enzyme in a cell, comprising the step of introducing a vector into the cell, wherein the vector comprises a stratum corneum chymotrytic enzyme gene in opposite orientation operably linked to elements necessary for expression. Expression of the vector produces SCCE antisense mRNA in the cell, which hybridizes to endogenous SCCE mRNA and thereby inhibits expression of SCCE in the cell.
In yet another embodiment of the present invention, there is provided a method of inhibiting stratum corneum chymotrytic enzyme protein in a cell, comprising the step of introducing an antibody specific for st

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Methods for the early diagnosis of ovarian cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods for the early diagnosis of ovarian cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for the early diagnosis of ovarian cancer will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-2528568

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.